Author

Jeffrey Neal

Observed names: J. Neal, Jeffrey S Neal

Institution: University of Kentucky

Observed institution: University of Kentucky

OpenAlex ID: A5113899062

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

2009 · Josef S Smolen, Jonathan Kay, et al. · The Lancet · 526

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

2022 · Philip J Mease, Atul A Deodhar, et al. · Annals of the Rheumatic Diseases · 222

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

2015 · Kevin L Winthrop, Joel Silverfield, et al. · Annals of the Rheumatic Diseases · 196

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study

2017 · Francisco J. Blanco, Rüdiger Möricke, et al. · Arthritis & Rheumatology · 186

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

2020 · Mark C. Genovese, Juan Sanchez-Burson, et al. · Arthritis Research & Therapy · 21

Pos1048 Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Psoriatic Arthritis: 52-week Results From a Randomised Phase 2 Trial

2022 · P.J. Mease, A. Deodhar, et al. · Annals of the Rheumatic Diseases · 5

OP0163 Evaluation of Influenza and Pneumococcal Vaccine Responses in Rheumatoid Arthritis Patients Using Tofacitinib

2013 · K.L. Winthrop, J. Neal, et al. · Annals of the Rheumatic Diseases · 4

Ab0377 Clinical Similarity of Abp 710 With Infliximab (reference Product) in Subjects With Moderate to Severe Rheumatoid Arthritis

2019 · Mark C. Genovese, Juan Sanchez-Burson, et al. · Annals of the Rheumatic Diseases · 1

Works count: 8

Citation count: 1,161

H-index: 5

I10-index: 5